seasonal allergic rhinitis
Conditions
Interventions
Control group 1:ake bilateral Zusanli, Fenglong, Xuehai and Taixi points. The patient takes a supine position, disinfects the skin at the acupuncture point, and uses a 1.5 inch acupuncture and moxibus
treatment group:Under ultrasound guidance, the needle is inserted from the depression in front of the mandibular coronoid process at the lower edge of the zygomatic arch, and inserted 55mm towards the
Control group 2:Select a unilateral pterygopalatine ganglion and use the same needle insertion position and angle as the ganglion acupuncture group, with a depth of about 10mm for shallow needling, wi
Sponsors
The Sixth Medical Center of PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) The patient may experience 2 or more symptoms such as paroxysmal sneezing watery nasal discharge nasal itching and nasal congestion with symptoms lasting or accumulating for more than 1 hour per day and may be accompanied by eye symptoms such as tearing eye itching and redness; 2) The patient presents with common signs such as pale nasal mucosa edema and watery nasal secretions; 3) The patient must be positive for at least one allergen SPT and/or serum specific IgE or positive for nasal provocation test. 4) The symptoms are severe and have a significant impact on quality of life. Common allergens include seasonal inhalants such as pollen and fungi. 5) Age range: 18-65 years old; 6) Disease duration = 2 years; 7) Nose Symptom Score Scale TNSS score = 4 points; 8) Voluntarily participate in this study and be able to cooperate in completing the follow-up work of this study understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Potential subjects who meet the inclusion criteria will be excluded if they meet any of the following criteria. 1) Individuals with a history of chronic sinusitis or those diagnosed with chronic sinusitis through X-ray examination; 2) Individuals with organic lesions in the nasal cavity or those who have undergone nasal surgery before; 3) Patients with combined asthma or other respiratory diseases such as bronchiectasis malignant lung lesions etc; 4) Individuals with combined liver and kidney dysfunction severe mental and psychological disorders or other serious illnesses; 5) Individuals who are allergic to or dizzy with the drugs used in the study; 6) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total nasal symptom score;VIP\NPY\CGRP and NE;VIP\NPY\CGRP and NE;Time domain heart rate variability analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| nasal resistance and Nasal Cavity Volume;total non-nasal symptom score;visual analogue scale;Skin resistance value at the end of the upper limb;rhinoconjunctivitis quality of life questionnaire; | — |
Countries
China
Contacts
Public ContactLing Guan
The Sixth Medical Center of PLA General Hospital
Outcome results
None listed